Utilize este identificador para referenciar este registo: http://hdl.handle.net/10362/129670
Título: Enhancing Discovery of Genetic Variants for Posttraumatic Stress Disorder Through Integration of Quantitative Phenotypes and Trauma Exposure Information
Autor: Maihofer, Adam X.
Choi, Karmel W.
Coleman, Jonathan R.I.
Daskalakis, Nikolaos P.
Denckla, Christy A.
Ketema, Elizabeth
Morey, Rajendra A.
Polimanti, Renato
Ratanatharathorn, Andrew
Torres, Katy
Wingo, Aliza P.
Austin, S. Bryn
Avdibegović, Esmina
Borglum, Anders D.
Babić, Dragan
Bækvad-Hansen, Marie
Baker, Dewleen G.
Beckham, Jean C.
Bierut, Laura J.
Bisson, Jonathan I.
Boks, Marco P.
McFarlane, Alexander
Bolger, Elizabeth A.
Bradley, Bekh
Brashear, Meghan
Breen, Gerome
Bryant, Richard A.
Bustamante, Angela C.
Bybjerg-Grauholm, Jonas
Calabrese, Joseph R.
JM, Caldas-de-Almeida
Chen, Chia Yen
McGlinchey, Regina E.
Dale, Anders M.
Dalvie, Shareefa
Deckert, Jürgen
Delahanty, Douglas L.
Dennis, Michelle F.
Disner, Seth G.
Domschke, Katharina
Duncan, Laramie E.
Džubur Kulenović, Alma
Erbes, Christopher R.
McLaughlin, Katie A.
Evans, Alexandra
Farrer, Lindsay A.
Feeny, Norah C.
Flory, Janine D.
Forbes, David
Franz, Carol E.
Galea, Sandro
Garrett, Melanie E.
Gautam, Aarti
Gelaye, Bizu
McLean, Samuel A.
Gelernter, Joel
Geuze, Elbert
Gillespie, Charles F.
Goçi, Aferdita
Gordon, Scott D.
Guffanti, Guia
Hammamieh, Rasha
Hauser, Michael A.
Heath, Andrew C.
Hemmings, Sian M.J.
Mehta, Divya
Hougaard, David Michael
Jakovljević, Miro
Jett, Marti
Johnson, Eric Otto
Jones, Ian
Jovanovic, Tanja
Qin, Xue Jun
Karstoft, Karen Inge
Kaufman, Milissa L.
Kessler, Ronald
Mellor, Rebecca
Khan, Alaptagin
Kimbrel, Nathan A.
King, Anthony P.
Koen, Nastassja
Kranzler, Henry R.
Kremen, William S.
Lawford, Bruce R.
Lebois, Lauren A.M.
Lewis, Catrin
Liberzon, Israel
Michopoulos, Vasiliki
Linnstaedt, Sarah D.
Logue, Mark W.
Lori, Adriana
Lugonja, Božo
Luykx, Jurjen J.
Lyons, Michael J.
Maples-Keller, Jessica L.
Marmar, Charles
Martin, Nicholas G.
Maurer, Douglas
Milberg, William
Mavissakalian, Matig R.
Miller, Mark W.
Morris, Charles Phillip
Zai, Clement C.
Mors, Ole
Mortensen, Preben B.
Nelson, Elliot C.
Nordentoft, Merete
Norman, Sonya B.
O'Donnell, Meaghan
Orcutt, Holly K.
Panizzon, Matthew S.
Peters, Edward S.
Peterson, Alan L.
Aiello, Allison E.
Peverill, Matthew
Pietrzak, Robert H.
Polusny, Melissa A.
Rice, John P.
Risbrough, Victoria B.
Roberts, Andrea L.
Rothbaum, Alex O.
Rothbaum, Barbara O.
Roy-Byrne, Peter
Ruggiero, Kenneth J.
Almli, Lynn M.
Rung, Ariane
Rutten, Bart P.F.
Saccone, Nancy L.
Sanchez, Sixto E.
Schijven, Dick
Seedat, Soraya
Seligowski, Antonia V.
Seng, Julia S.
Sheerin, Christina M.
Silove, Derrick
Amstadter, Ananda B.
Smith, Alicia K.
Smoller, Jordan W.
Sponheim, Scott R.
Stein, Dan J.
Stevens, Jennifer S.
Teicher, Martin H.
Thompson, Wesley K.
Trapido, Edward
Uddin, Monica
Ursano, Robert J.
Andersen, Soren B.
van den Heuvel, Leigh Luella
Van Hooff, Miranda
Vermetten, Eric
Vinkers, Christiaan
Voisey, Joanne
Wang, Yunpeng
Wang, Zhewu
Werge, Thomas
Williams, Michelle A.
Williamson, Douglas E.
Andreassen, Ole A.
Winternitz, Sherry
Wolf, Christiane
Wolf, Erika J.
Yehuda, Rachel
Young, Keith A.
Young, Ross Mc D.
Zhao, Hongyu
Zoellner, Lori A.
Haas, Magali
Lasseter, Heather
Arbisi, Paul A.
Provost, Allison C.
Salem, Rany M.
Sebat, Jonathan
Shaffer, Richard A.
Wu, Tianying
Ripke, Stephan
Daly, Mark J.
Ressler, Kerry J.
Koenen, Karestan C.
Stein, Murray B.
Ashley-Koch, Allison E.
Nievergelt, Caroline M.
Palavras-chave: Genetics
GWAS
Heritability
PheWAS
PTSD
Trauma
Biological Psychiatry
Data: 1-Abr-2022
Resumo: Background: Posttraumatic stress disorder (PTSD) is heritable and a potential consequence of exposure to traumatic stress. Evidence suggests that a quantitative approach to PTSD phenotype measurement and incorporation of lifetime trauma exposure (LTE) information could enhance the discovery power of PTSD genome-wide association studies (GWASs). Methods: A GWAS on PTSD symptoms was performed in 51 cohorts followed by a fixed-effects meta-analysis (N = 182,199 European ancestry participants). A GWAS of LTE burden was performed in the UK Biobank cohort (N = 132,988). Genetic correlations were evaluated with linkage disequilibrium score regression. Multivariate analysis was performed using Multi-Trait Analysis of GWAS. Functional mapping and annotation of leading loci was performed with FUMA. Replication was evaluated using the Million Veteran Program GWAS of PTSD total symptoms. Results: GWASs of PTSD symptoms and LTE burden identified 5 and 6 independent genome-wide significant loci, respectively. There was a 72% genetic correlation between PTSD and LTE. PTSD and LTE showed largely similar patterns of genetic correlation with other traits, albeit with some distinctions. Adjusting PTSD for LTE reduced PTSD heritability by 31%. Multivariate analysis of PTSD and LTE increased the effective sample size of the PTSD GWAS by 20% and identified 4 additional loci. Four of these 9 PTSD loci were independently replicated in the Million Veteran Program. Conclusions: Through using a quantitative trait measure of PTSD, we identified novel risk loci not previously identified using prior case-control analyses. PTSD and LTE have a high genetic overlap that can be leveraged to increase discovery power through multivariate methods.
Descrição: Funding Information: This work was supported by the National Institute of Mental Health / U.S. Army Medical Research and Development Command (Grant No. R01MH106595 [to CMN, IL, MBS, KJRe, and KCK], National Institutes of Health (Grant No. 5U01MH109539 to the Psychiatric Genomics Consortium ), and Brain & Behavior Research Foundation (Young Investigator Grant [to KWC]). Genotyping of samples was provided in part through the Stanley Center for Psychiatric Genetics at the Broad Institute supported by Cohen Veterans Bioscience . Statistical analyses were carried out on the LISA/Genetic Cluster Computer ( https://userinfo.surfsara.nl/systems/lisa ) hosted by SURFsara. This research has been conducted using the UK Biobank resource (Application No. 41209). This work would have not been possible without the financial support provided by Cohen Veterans Bioscience, the Stanley Center for Psychiatric Genetics at the Broad Institute, and One Mind. Funding Information: MBS has in the past 3 years received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech and has stock options in Oxeia Biopharmaceuticals and Epivario. In the past 3 years, NPD has held a part-time paid position at Cohen Veterans Bioscience, has been a consultant for Sunovion Pharmaceuticals, and is on the scientific advisory board for Sentio Solutions for unrelated work. In the past 3 years, KJRe has been a consultant for Datastat, Inc., RallyPoint Networks, Inc., Sage Pharmaceuticals, and Takeda. JLM-K has received funding and a speaking fee from COMPASS Pathways. MU has been a consultant for System Analytic. HRK is a member of the Dicerna scientific advisory board and a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative, which during the past 3 years was supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka. HRK and JG are named as inventors on Patent Cooperative Treaty patent application number 15/878,640, entitled “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. RP and JG are paid for their editorial work on the journal Complex Psychiatry. OAA is a consultant to HealthLytix. All other authors report no biomedical financial interests or potential conflicts of interest. Funding Information: This work was supported by the National Institute of Mental Health/ U.S. Army Medical Research and Development Command (Grant No. R01MH106595 [to CMN, IL, MBS, KJRe, and KCK], National Institutes of Health (Grant No. 5U01MH109539 to the Psychiatric Genomics Consortium), and Brain & Behavior Research Foundation (Young Investigator Grant [to KWC]). Genotyping of samples was provided in part through the Stanley Center for Psychiatric Genetics at the Broad Institute supported by Cohen Veterans Bioscience. Statistical analyses were carried out on the LISA/Genetic Cluster Computer (https://userinfo.surfsara.nl/systems/lisa) hosted by SURFsara. This research has been conducted using the UK Biobank resource (Application No. 41209). This work would have not been possible without the financial support provided by Cohen Veterans Bioscience, the Stanley Center for Psychiatric Genetics at the Broad Institute, and One Mind. This material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting true views of the U.S. Department of the Army or the Department of Defense. We thank the investigators who comprise the PGC-PTSD working group and especially the more than 206,000 research participants worldwide who shared their life experiences and biological samples with PGC-PTSD investigators. We thank Mark Zervas for his critical input. Full acknowledgments are in Supplement 1. MBS has in the past 3 years received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech and has stock options in Oxeia Biopharmaceuticals and Epivario. In the past 3 years, NPD has held a part-time paid position at Cohen Veterans Bioscience, has been a consultant for Sunovion Pharmaceuticals, and is on the scientific advisory board for Sentio Solutions for unrelated work. In the past 3 years, KJRe has been a consultant for Datastat, Inc. RallyPoint Networks, Inc. Sage Pharmaceuticals, and Takeda. JLM-K has received funding and a speaking fee from COMPASS Pathways. MU has been a consultant for System Analytic. HRK is a member of the Dicerna scientific advisory board and a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative, which during the past 3 years was supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka. HRK and JG are named as inventors on Patent Cooperative Treaty patent application number 15/878,640, entitled ?Genotype-guided dosing of opioid agonists,? filed January 24, 2018. RP and JG are paid for their editorial work on the journal Complex Psychiatry. OAA is a consultant to HealthLytix. All other authors report no biomedical financial interests or potential conflicts of interest. Publisher Copyright: © 2021 Society of Biological Psychiatry
Peer review: yes
URI: http://hdl.handle.net/10362/129670
DOI: https://doi.org/10.1016/j.biopsych.2021.09.020
ISSN: 0006-3223
Aparece nas colecções:NMS: CEDOC - Artigos em revista internacional com arbitragem científica

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
1_s2.0_S0006322321016322_main.pdf931,35 kBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.